Alloy / M4 Eye Cream Rx
ESTRIOL 1% + PEPTIDES
The most completely specified product in this register — estriol 1%, palmitoyl pentapeptide-4 0.1%, acetyl hexapeptide-8 0.1%, a full ingredient list, and results labelled by whether an instrument or an assessor produced them. It is also five times the concentration of Alloy's body cream, applied to the thinnest skin on the face, millimetres from the meibomian glands, with no ophthalmic guidance of any kind.
There is a real reason to hesitate. Read the finding before you buy.
ASSESSED ON 75% OF THE MODEL. 2 CRITERIA LEFT UNSCORED — SEE SCORING FOR WHY.
Ask why this is 1% when the body cream is 0.2%, and ask what to do if it gets in your eye. Neither question is answered on the page.
The verdict
This is the best-specified product we have assessed, and it is not close. The Ingredients tab reads: 'Full list of ingredients: estriol 1%, palmitoyl pentapeptide-4 0.1%, acetyl hexapeptide-8 0.1%, C12-15 alkyl benzoate...' and continues through every excipient. Three actives, three concentrations, and a complete INCI. Nothing else in thirty reviews publishes the strength of its secondary actives — Obagi gives one number, Dermatica gives actives without a base, Ro and the M4 face cream give a base without numbers. This gives all of it.
The evidence presentation is the best here too, and by the same margin. The results in the Details tab carry footnote markers distinguishing how each was obtained: up to 40% more elasticity and up to 40% less crepiness on the eyelids, marked 'Based on Expert Assessment'; a 23% immediate boost in hydration, marked 'Based on Instrumentation'. We criticised the body treatment two reviews ago for running four instruments and publishing only the questionnaire. Here Alloy runs the same four instruments, on n=34 over twelve weeks, and tells you which number came from which method. That is the practice we have been asking twenty-nine products for.
Then the concentration. This eye cream is estriol 1%. Alloy's body treatment is 0.2%. The controlled facial trials that underpin the entire M4 safety story used 0.3%. So the highest estriol concentration in the range — more than three times the studied concentration — is the one applied to periorbital skin, which is the thinnest and most permeable skin on the face. The page does not explain the choice, or acknowledge that it is one.
And this is an eye product with nothing ophthalmic in it. No instruction about avoiding the lash line or the lid margin, nothing about what to do if it gets in the eye, and no mention of dry eye — from a menopause company, in a demographic where dry eye is common, applying an estrogen a few millimetres from the meibomian glands, which the literature says estrogen inhibits. Alongside the same empty Safety Information section its two siblings carry, that is enough to keep this at caution however well the rest is documented.
- Publishes three concentrations — estriol 1%, palmitoyl pentapeptide-4 0.1%, acetyl hexapeptide-8 0.1% — alongside a full ingredient list.
- The only product in thirty reviews to publish the strength of its secondary actives.
- Labels every quantified result by method: 'Based on Expert Assessment' or 'Based on Instrumentation'.
- Reports actual magnitudes — up to 40% more elasticity, up to 40% less eyelid crepiness, a 23% immediate hydration boost — rather than only proportions of users.
- Discloses the study's sample size (n=34) and duration, and names all four instruments used.
- Acetyl hexapeptide-8 is correctly matched to crow's feet, which are genuinely expression lines.
- Names a medical reviewer with their role — Dr Michelle Montville, Clinical Director and Prescribing Physician.
- $30 a month, the cheapest of the three M4 products, with unlimited doctor access, delivery and HSA/FSA eligibility included.
- Treats a real and specific complaint — periorbital crepiness and wrinkle depth after menopause.
- Estriol 1% — five times the body treatment and more than three times the studied facial concentration — on the thinnest skin on the face, with no rationale given.
- No ophthalmic guidance of any kind on an eye product: nothing about the lid margin, the lash line, or contact with the eye.
- No mention of dry eye, from a menopause company applying an estrogen beside the meibomian glands.
- Zero mentions of side effects, contra-indications, pregnancy or breast cancer.
- The Safety Information tab contains a product description, as on both sibling pages.
- No fill size and no application quantity.
- No control arm described, and 'up to 40%' is a ceiling rather than an average.
- The four headline carousel figures are still self-reported, while the better-attributed numbers sit in a tab below.
- '97% saw a 23% boost in skin hydration' conflates a proportion of users with a magnitude of change.
- Named 'M4 Eye Cream Rx' on the page, 'M4 Eye Serum' in a heading, and 'eye serum' in the URL.
- Compounded status unstated, as across the range.
Every active, assessed
- Estriol1%
Weak estrogen — binds dermal estrogen receptors, stimulates fibroblast collagen and hyaluronic acid synthesis
- BENCHMARK
- 0.3% is the concentration used in the controlled facial trials
- ASSESSMENT
- Published, which is right, and unexplained, which is not. Periorbital skin is the thinnest on the face and absorbs more per unit area than any other facial site, so this is the highest concentration in the range going onto the most permeable target. The mitigating fact is genuine — the area is very small, so total applied dose is low — but the page makes neither the choice nor the mitigation explicit, and a five-fold difference from the same company's body product invites the question.
- Palmitoyl Pentapeptide-40.1%
Signal peptide — upregulates collagen and fibronectin
- BENCHMARK
- Commonly used at low parts-per-million of active peptide
- ASSESSMENT
- A reasonable partner for an estrogen aimed at collagen, and the first time any product in this register has published a peptide's concentration. Whether 0.1% refers to the raw material or the peptide itself is not stated, which is the next question — but a number is a great deal more than the 'peptide complex' the category usually offers.
- Acetyl Hexapeptide-80.1%
Neuropeptide — marketed to soften expression lines by interfering with neurotransmitter release
- BENCHMARK
- Facial expression lines are its only claimed indication
- ASSESSMENT
- Correctly placed, which we should say plainly having criticised it on the body treatment. Crow's feet are expression lines caused by orbicularis contraction — exactly what this peptide is sold for. The same ingredient that was decorative on a knee is on-indication here, and the page describes it accurately as helping prevent expression lines.
| ACTIVE | CONC. | BENCHMARK | ASSESSMENT |
|---|---|---|---|
| EstriolWeak estrogen — binds dermal estrogen receptors, stimulates fibroblast collagen and hyaluronic acid synthesis | 1% | 0.3% is the concentration used in the controlled facial trials | Published, which is right, and unexplained, which is not. Periorbital skin is the thinnest on the face and absorbs more per unit area than any other facial site, so this is the highest concentration in the range going onto the most permeable target. The mitigating fact is genuine — the area is very small, so total applied dose is low — but the page makes neither the choice nor the mitigation explicit, and a five-fold difference from the same company's body product invites the question. |
| Palmitoyl Pentapeptide-4Signal peptide — upregulates collagen and fibronectin | 0.1% | Commonly used at low parts-per-million of active peptide | A reasonable partner for an estrogen aimed at collagen, and the first time any product in this register has published a peptide's concentration. Whether 0.1% refers to the raw material or the peptide itself is not stated, which is the next question — but a number is a great deal more than the 'peptide complex' the category usually offers. |
| Acetyl Hexapeptide-8Neuropeptide — marketed to soften expression lines by interfering with neurotransmitter release | 0.1% | Facial expression lines are its only claimed indication | Correctly placed, which we should say plainly having criticised it on the body treatment. Crow's feet are expression lines caused by orbicularis contraction — exactly what this peptide is sold for. The same ingredient that was decorative on a knee is on-indication here, and the page describes it accurately as helping prevent expression lines. |
Scoring
- EVIDENCE FOR THE ACTIVEWEIGHT 30%72/100
The strongest evidence presentation in the register: n=34 over twelve weeks, four named instruments, and — uniquely — every quantified result labelled according to whether an assessor or an instrument produced it. Held back because no control arm is described, because 'up to 40%' states a ceiling rather than a mean, because the four carousel headlines remain self-reported, and because 1% sits well above the concentration the facial literature actually studied.
- FORMULATION INTEGRITYWEIGHT 20%74/100
The most completely specified formula we have assessed — three actives with three concentrations plus a full excipient list — and the peptides are matched to the indication rather than decorating it. Marked down because the range's highest estriol concentration is placed on its most permeable site with no rationale offered, and because there is still no fill size and no application quantity for a prescription hormone.
- DISCLOSUREWEIGHT 15%40/100
Composition and evidence-method disclosure are both the best in the register. Safety disclosure is unchanged from its two siblings: side effects, contra-indications, pregnancy and breast cancer each appear zero times, under a tab headed Safety Information that contains a product description. New here and specific to the site: no ophthalmic instruction, nothing about contact with the eye, and no mention of dry eye on an estrogen applied beside the meibomian glands.
- TOLERANCE IN USEWEIGHT 15%NOT ASSESSED
Not assessed, and the periorbital area is where it would matter most — this is the site most prone to stinging, migration and irritation from anything applied nearby. The page offers no adverse-effect profile to check a panel against.
- TEXTURE & WEARWEIGHT 10%NOT ASSESSED
Not assessed. Requires the product in hand across the twelve-week window.
- COST PER APPLICATIONWEIGHT 10%62/100
$90 for a stated three-month supply is $30 a month, the cheapest of the three M4 products and the cheapest hormone product in this register — and eye creams are applied in genuinely small amounts, so a bottle plausibly does last. Held back by the same missing fill size as its siblings, which means the three-month claim cannot be checked against the amount you are told to use, because you are not told.
What it is
A prescription topical estrogen for the periorbital area, built around estriol at 1% with two peptides, aimed at crow's feet, crepiness and loss of firmness around the eyes after menopause. $90 for a stated three-month supply — $30 a month — including unlimited access to a menopause-trained physician, free delivery and HSA/FSA eligibility.
The best-specified product in the register
Thirty reviews in, here is the Ingredients tab, quoted as published:
Full list of ingredients: estriol 1%, palmitoyl pentapeptide-4 0.1%, acetyl hexapeptide-8 0.1%, C12-15 alkyl benzoate, caprylic/capric triglyceride, cetyl alcohol, ethylhexylglycerin, glycerin, glyceryl stearate, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, oleic acid, olea europaea (olive) fruit oil, PEG-100 stearate, phenoxyethanol, dimethicone, polymethylsiloxane, water (aqua), stearic acid, trolamine, tocopheryl (vitamin E) acetate.
Alloy, M4 Eye Cream Rx, Ingredients tab
Three actives, three concentrations, then every excipient. No other product we have assessed publishes the strength of its secondary actives — not Obagi, which gives one number and a full excipient list; not Dermatica, which gives actives and no base; not Ro or the M4 face cream, which give a base and no numbers. This is the only page where a reader can reconstruct the whole formula.
Two reviews ago we criticised the M4 body treatment for running Corneometer, Cutometer, Moisturemeter and Antera 3D and then headlining the questionnaire. Here the same four instruments are run on n=34, and the Details tab reports 'up to 40% more elasticity' and 'up to 40% less crepiness on the eyelids' marked '*Based on Expert Assessment', and '23% immediate boost in hydration' marked '**Based on Instrumentation'. Telling a reader which number came from a machine and which from a grader is the single most useful evidential thing any company here has done.
One per cent, on the thinnest skin on the face
Having praised the disclosure, the disclosure is what makes the next finding possible. Because Alloy publishes its concentrations, we can line the range up.
The M4 face cream publishes no concentration, so it cannot appear. The highest strength in the range is on the most permeable skin, and it is more than three times the concentration used in the controlled facial trials the line's safety case rests on.
Periorbital skin is the thinnest on the face and among the most permeable on the body, which is why eye products are conventionally formulated gently rather than strongly. Alloy has gone the other way, and the page neither explains the decision nor acknowledges making one.
The honest mitigation is real and we will supply it since the page does not: the eye area is tiny, an eye cream is applied in very small quantities, and total hormone exposure from this product is almost certainly lower than from the body treatment despite the five-fold concentration difference. Per unit area it is the range's most concentrated exposure; in absolute terms it is probably its smallest. That is the sentence the page needed and does not contain.
An eye product with nothing ophthalmic in it
We searched the page for anything about the eye itself, as distinct from the skin around it. There is no instruction about the lash line or the lid margin, nothing about avoiding contact with the eye, nothing about what to do if it gets in, and no mention of dry eye or the ocular surface.
That last one is a specific gap rather than a general one, and it is worth being precise about why. The meibomian glands sit in the eyelid margin, a few millimetres from where this cream is applied, and secrete the lipid layer that stops tears evaporating. Estrogen is documented to inhibit meibomian lipid synthesis, and dry eye is more prevalent in postmenopausal women on estrogen therapy — a case series has recorded near-total meibomian gland loss in women on long-term estrogen-progesterone supplementation.
That literature concerns systemic estrogen, and a small quantity of 1% estriol on periorbital skin is a different exposure entirely. There is no evidence that this product affects the ocular surface, and it may well not. The finding is narrower and firmer than that: this is an estrogen applied daily, indefinitely, millimetres from a hormone-responsive gland, marketed by a menopause company to the exact population in which dry eye is most common — and the page does not raise the question, answer it, or say a word about the eye. Of all the companies in this register, this is the one that would know the literature.
The peptide is in the right place this time
We were hard on the body treatment for including acetyl hexapeptide-8, a peptide sold on its ability to soften expression lines, in a product for chests, knees and legs — sites that do not have any. It is only fair to note that on this page it belongs.
Crow's feet are expression lines, produced by repeated contraction of the orbicularis oculi. This is the one site in the M4 range where a neuropeptide aimed at expression lines has a coherent rationale, and the page describes it accurately as helping prevent them. The same ingredient, correctly placed, at a published concentration.
And the same empty Safety Information
Three M4 pages, three tabs headed Safety Information, three containing a product description, an ingredient list, who it is for, what you get and how to order.
Side effects: zero mentions. Contra-indications: zero. Pregnancy: zero. Breast cancer: zero. What was an oversight on one page and a convention across two is now, at three for three, simply how this company builds product pages. It is the more striking here because everything else on this page has improved — the concentrations, the peptide strengths, the method attribution — which shows the capability is present and has not been pointed at safety.
If you are considering it
- Ask why the eye product is 1% when the body product is 0.2%. It may be a good answer; the page does not attempt one.
- Ask how much to apply and how much is in the bottle. Neither is stated anywhere in the range.
- Keep it well away from the lash line and lid margin, and do not apply to the eyelid itself unless a clinician tells you to.
- If you have dry eye, blepharitis or meibomian gland dysfunction, raise it with an eye clinician before starting.
- If you have any history of hormone-sensitive cancer, or take tamoxifen or an aromatase inhibitor, ask a specialist — the page is silent.
- Read the Details tab rather than the headline figures. The numbers there are labelled by method and are the better information.
- Give it twelve weeks, which is the study window and the page's own timeline.
Where we stand
At 65 this is the highest-scoring product we have marked CAUTION, and the highest of the three M4 products by seven points. It earns that on documentation: this is the only page in thirty reviews where a buyer can read every ingredient and the strength of every active, and the only one that tells you whether a result came from an instrument or an assessor. Both are practices we have spent the whole register asking for, and Alloy has simply done them.
The caution is for two things the documentation makes visible rather than hides. The range's strongest hormone concentration sits on its most permeable skin, unexplained. And an eye product carries no ophthalmic guidance at all, from a menopause company, beside a gland that estrogen is known to act on — alongside the same empty safety section its two siblings carry.
The fixes are now the same three, for the third time, and this page is one short paragraph from being genuinely exemplary. Put safety information under the heading marked Safety Information. Say why 1% is right here. Add a line about the eye. Alloy has already proved on this very page that it can publish anything it decides to publish.
Who this is for
- A perimenopausal or menopausal woman with periorbital crepiness and fine lines, no history of hormone-sensitive cancer, and no ocular surface disease.
- Someone who wants to know exactly what is in the bottle and at what strength — this is the only page in the register that fully answers that.
- Someone who will ask why this is 1% when the body product is 0.2%, and get a real answer.
- Someone who will keep it well away from the lash line and lid margin on their own initiative, because the page will not say so.
- Someone who wants the peptides where they actually belong — crow's feet are the one place acetyl hexapeptide-8 makes sense.
- You have a history of breast, endometrial or other hormone-sensitive cancer, or take tamoxifen or an aromatase inhibitor. The page says nothing; ask a specialist.
- You have dry eye, meibomian gland dysfunction or any ocular surface disease. The interaction is unstudied here and unaddressed on the page — raise it with an eye clinician first.
- You are pregnant or breastfeeding. No position is offered.
- You wear contact lenses and are prone to irritation from products migrating into the eye.
- You want to know how much to apply, or how much is in the bottle.
Ask why this is 1% when the body cream is 0.2%, and ask what to do if it gets in your eye. Neither question is answered on the page.
This is an editorial assessment of published information about a prescription product. It is not a diagnosis, not a prescription and not a substitute for your own prescriber. Hydroquinone and tretinoin are drugs. Decisions about them belong with a clinician who has seen your skin.
Sources
- S-01Alloy — M4 Eye Cream Rx product page The $90 three-month price, the full ingredient list with estriol 1% and both peptides at 0.1%, the n=34 twelve-week study footnote naming four instruments, the results labelled 'Based on Expert Assessment' and 'Based on Instrumentation', the named medical reviewer, and the absence of ophthalmic, side-effect, contra-indication, pregnancy and breast cancer content. Read 28 July 2026.
- S-02Alloy — M4 Body Treatment Rx product page Estriol 0.2%, the comparator in Fig. 1, and the sibling product where the same peptide appears without a matching indication.
- S-03Schmidt et al. — Treatment of skin ageing with topical estrogens (Int J Dermatol, 1996) 0.3% estriol on facial skin in 59 women over six months with no significant change in serum FSH, prolactin or estradiol — the studied concentration in Fig. 1.
- S-04Sex hormones and dry eye disease: current update The documented relationship between estrogen and meibomian gland lipid synthesis, and the higher prevalence of dry eye in postmenopausal women on estrogen therapy.
- S-05Severe meibomian gland loss in polycystic ovarian syndrome patients on estrogen-progesterone therapy (case series) Near-total meibomian gland loss recorded in women on long-term systemic estrogen-progesterone supplementation — systemic exposure, not topical, and cited here only to establish that the gland is hormone-responsive.
- S-06NASEM — The Clinical Utility of Compounded Bioidentical Hormone Therapy Confirms no FDA-approved estriol product exists in the United States, so this preparation is compounded — a status the page does not state.